HanAll to complete Phase II study for Hanferon in U.S. by next February
Published: 2011-11-11 06:57:00
Updated: 2011-11-11 06:57:00
HanAll BioPharma plans to complete Phase II clinical trial for its biosimilar product Hanferon (interferon alpha; HL-143) in the U.S. during February 2012, as the drug has been successfully administered to all patients in six U.S. hospitals since its first dosing on July 6.
Biosimilars, or imi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
